Crossref
India: regulator’s list of 50 substandard drugs raises questions about oversight and manufacturing
BMJ · 2024
DOI: 10.1136/bmj.q2149 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMJ, 2024. Verfasst von Neeta Lal. Beteiligte Einrichtung: New Delhi. Hauptthemen laut MEDLINE: Drug Industry. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Drug IndustryIndiaHumansPharmaceutical PreparationsDrug and Narcotic ControlQuality Control
Substanzen
Pharmaceutical Preparations
Autor:innen und Institutionen
- New Delhi.
Zitieren
APA
Lal, N. (2024). India: regulator’s list of 50 substandard drugs raises questions about oversight and manufacturing. BMJ. https://doi.org/10.1136/bmj.q2149
Vancouver
Lal N. India: regulator’s list of 50 substandard drugs raises questions about oversight and manufacturing. BMJ. 2024. doi:10.1136/bmj.q2149
BibTeX
@article{Lal2024,
author = {Lal, Neeta},
title = {India: regulator’s list of 50 substandard drugs raises questions about oversight and manufacturing},
journal = {BMJ},
year = {2024},
doi = {10.1136/bmj.q2149}
}
EUVIMED